expenses (7.95) (9.36) (1.42) 17.85% (15.79) (18.47) (2.68) 16.98% Other expenses (1.54) (1.10) 0.44 -28.39% (1.47) (2.25) (0.79) 53.66% Profit from operating activities 12.91 1.22 (11.70) -90.58% 37.93 3.84
-74.72% Operating results for each business segment are shown below: 1. Manufacturing and Selling of Special Cutting Tools unit: THB million 2019 2018 Change (THB million) Change (%) Revenue from External
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
customers. The subsidiaries overseas were also affected by the strengthening of Thai Baht, which resulted in a decline in total value when converting their operating results from local currencies to Thai Baht
Section 114 Securities and Exchange Act B.E. 2535 Section 114. In operating the business of securities dealing, a securities company shall comply with the rules, conditions and procedures as
Notification of the Securities and Exchange Commission KorThor 17/2560 Rules, Conditions and Procedures for Applying for Licenses and Granting Licenses for Operating Securities Clearing House
Consolidated Financial Statements ended 31 December 2017, which have been audited by the Company’s authorized auditor. The company would like to clarify the operating results of the Company and its subsidiary
period of previous year as loss of 268.24 Million Baht by following details Analysis of operating results (1) Revenue Quarter 2/2020 Company and its subsidiaries has total revenue of 663.43 Million Baht as
Website: www.kiatnakin.co.th http://www.kiatnakin.co.th/ 2 Management Discussion and Analysis (MD&A) For the first quarter ended March 31, 2020 comparing operating performance and financial position for the